Skip to main content
Top
Published in: Journal of Interventional Cardiac Electrophysiology 3/2022

03-07-2021 | Sudden Cardiac Death

The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis

Authors: Ioannis Anagnostopoulos, Maria Kousta, Charalampos Kossyvakis, Eleni Lakka, Nikolaos Taxiarchis Paraskevaidis, Nikolaos Schizas, Nikolaos Alexopoulos, Spyridon Deftereos, Georgios Giannopoulos

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 3/2022

Login to get access

Abstract

Background

Previous studies suggest that late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) is associated with arrhythmic events in patients with nonischemic cardiomyopathy (NICM), while others have questioned the role of left ventricular ejection fraction (LVEF) as a sole predictor of future events.

Objectives

To evaluate the role of LGE on CMR in identifying patients with NICM and reduced LVEF for whom a benefit from defibrillator implantation for primary prevention is not anticipated, thus they are mainly exposed to potential risks.

Methods

Major electronic databases were searched for studies reporting the incidence of appropriate device therapy (ADT), sudden cardiac death (SCD), and cardiac death based on the presence of LGE on CMR, among patients with NICM and reduced LVEF, implanted with a cardioverter defibrillator for primary prevention.

Results

Eleven studies (1652 patients, 947 with LGE) were included in the final analysis. LGE presence was strongly associated with ADT (logOR: 1.95, 95%CI: 1.21–2.69) and cardiac death (logOR: 0.91, 95%CI: 0.14–1.68), but not with SCD (logOR: 0.26, 95%CI: −1.09–1.6). Diagnostic accuracy analysis demonstrated that contrast enhancement is a sensitive marker of future ADT and cardiac death (93%, 95%CI: 85.8–96.7%; 82.9%, 95%CI: 70.6–90.7%; respectively), with moderate specificity ( 44%, 95%CI: 27.2–62.6%; 37.7%, 95%CI: 23.4–54.6%; respectively).

Conclusion

LGE is a highly sensitive predictor of ADT and cardiac death in NICM patients implanted with a defibrillator for primary prevention. However, due to moderate specificity, derivation of a cutoff with adequate predictive values and probably a multifactorial approach are needed to improve discrimination of patients who will not benefit from ICDs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kadowaki S, Watanabe T, Otaki Y, Narumi T, Honda Y, Takahashi H, et al. Combined assessment of myocardial damage and electrical disturbance in chronic heart failure. World J Cardiol. 2017;9(5):457–65.CrossRef Kadowaki S, Watanabe T, Otaki Y, Narumi T, Honda Y, Takahashi H, et al. Combined assessment of myocardial damage and electrical disturbance in chronic heart failure. World J Cardiol. 2017;9(5):457–65.CrossRef
2.
go back to reference Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J. 2017;38(22):1738–46.CrossRef Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J. 2017;38(22):1738–46.CrossRef
3.
go back to reference Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.CrossRef Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.CrossRef
4.
go back to reference Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12(11):1564–70.CrossRef Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12(11):1564–70.CrossRef
5.
go back to reference de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol. 2011;57(6):630–8.CrossRef de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol. 2011;57(6):630–8.CrossRef
6.
go back to reference Disertori M, Rigoni M, Pace N, Casolo G, Masè M, Gonzini L, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: A Meta-Analysis. JACC Cardiovasc Imaging. 2016;9(9):1046–55.CrossRef Disertori M, Rigoni M, Pace N, Casolo G, Masè M, Gonzini L, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: A Meta-Analysis. JACC Cardiovasc Imaging. 2016;9(9):1046–55.CrossRef
7.
go back to reference Breitenstein A, Steffel J. Devices in heart failure patients-who benefits from ICD and CRT? Front Cardiovasc Med. 2019;6:111.CrossRef Breitenstein A, Steffel J. Devices in heart failure patients-who benefits from ICD and CRT? Front Cardiovasc Med. 2019;6:111.CrossRef
8.
go back to reference Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging. 2018;11(9):1274–84.CrossRef Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging. 2018;11(9):1274–84.CrossRef
9.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.CrossRef
11.
go back to reference Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34.CrossRef Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34.CrossRef
12.
go back to reference Chimura M, Kiuchi K, Okajima K, et al. Distribution of ventricular fibrosis associated with life-threatening ventricular tachyarrhythmias in patients with nonischemic dilated cardiomyopathy. J CardiovascElectrophysiol. 2015;26(11):1239–46.CrossRef Chimura M, Kiuchi K, Okajima K, et al. Distribution of ventricular fibrosis associated with life-threatening ventricular tachyarrhythmias in patients with nonischemic dilated cardiomyopathy. J CardiovascElectrophysiol. 2015;26(11):1239–46.CrossRef
13.
go back to reference Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J AmCollCardiol. 2008;51(25):2414–21.CrossRef Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J AmCollCardiol. 2008;51(25):2414–21.CrossRef
14.
go back to reference Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J AmCollCardiol. 2011;57(7):821–8.CrossRef Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J AmCollCardiol. 2011;57(7):821–8.CrossRef
15.
go back to reference Neilan TG, Coelho-Filho OR, Danik SB, Shah RV, Dodson JA, Verdini DJ, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(9):944–54.CrossRef Neilan TG, Coelho-Filho OR, Danik SB, Shah RV, Dodson JA, Verdini DJ, et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(9):944–54.CrossRef
16.
go back to reference Mordi I, Jhund PS, Gardner RS, Payne J, Carrick D, Berry C, et al. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. JACC CardiovascImaging. 2014;7(6):561–9.CrossRef Mordi I, Jhund PS, Gardner RS, Payne J, Carrick D, Berry C, et al. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. JACC CardiovascImaging. 2014;7(6):561–9.CrossRef
17.
go back to reference Piers SR, Everaerts K, van der Geest RJ, et al. Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm. 2015;12(10):2106–14.CrossRef Piers SR, Everaerts K, van der Geest RJ, et al. Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm. 2015;12(10):2106–14.CrossRef
18.
go back to reference Voskoboinik A, Bloom J, Taylor A, Mariani J. Early implantation of primary prevention implantable cardioverter defibrillators for patients with newly diagnosed severe nonischemic cardiomyopathy. PacingClinElectrophysiol. 2016;39(9):992–8. Voskoboinik A, Bloom J, Taylor A, Mariani J. Early implantation of primary prevention implantable cardioverter defibrillators for patients with newly diagnosed severe nonischemic cardiomyopathy. PacingClinElectrophysiol. 2016;39(9):992–8.
19.
go back to reference Marume K, Noguchi T, Tateishi E, et al. Mortality and sudden cardiac death risk stratification using the noninvasive combination of wide QRS duration and late gadolinium enhancement in idiopathic dilated cardiomyopathy. CircArrhythmElectrophysiol. 2018;11(4):e006233. Marume K, Noguchi T, Tateishi E, et al. Mortality and sudden cardiac death risk stratification using the noninvasive combination of wide QRS duration and late gadolinium enhancement in idiopathic dilated cardiomyopathy. CircArrhythmElectrophysiol. 2018;11(4):e006233.
20.
go back to reference Gutman SJ, Costello BT, Papapostolou S, Voskoboinik A, Iles L, Ja J, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J. 2019;40(6):542–50.CrossRef Gutman SJ, Costello BT, Papapostolou S, Voskoboinik A, Iles L, Ja J, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J. 2019;40(6):542–50.CrossRef
21.
go back to reference Muthalaly RG, Kwong RY, John RM, van der Geest R, Tao Q, Schaeffer B, et al. Left ventricular entropy is a novel predictor of arrhythmic events in patients with dilated cardiomyopathy receiving defibrillators for primary prevention. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1177–84.CrossRef Muthalaly RG, Kwong RY, John RM, van der Geest R, Tao Q, Schaeffer B, et al. Left ventricular entropy is a novel predictor of arrhythmic events in patients with dilated cardiomyopathy receiving defibrillators for primary prevention. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1177–84.CrossRef
22.
go back to reference Barison A, Aimo A, Mirizzi G, Castiglione V, Ripoli A, Panchetti L, et al. The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. Int J Cardiol. 2020;307:180–6.CrossRef Barison A, Aimo A, Mirizzi G, Castiglione V, Ripoli A, Panchetti L, et al. The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. Int J Cardiol. 2020;307:180–6.CrossRef
23.
go back to reference Alba AC, Gaztañaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D, et al. Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy: An International, Multi-Institutional Study of the MINICOR Group. Circ Cardiovasc Imaging. 2020;13(4):e010105.CrossRef Alba AC, Gaztañaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D, et al. Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy: An International, Multi-Institutional Study of the MINICOR Group. Circ Cardiovasc Imaging. 2020;13(4):e010105.CrossRef
24.
go back to reference Linhart M, Doltra A, Acosta J, Borràs R, Jáuregui B, Fernández-Armenta J, et al. Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. Europace. 2020;22(9):1391–400.CrossRef Linhart M, Doltra A, Acosta J, Borràs R, Jáuregui B, Fernández-Armenta J, et al. Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. Europace. 2020;22(9):1391–400.CrossRef
25.
go back to reference Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.CrossRef Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.CrossRef
26.
go back to reference Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453–8.CrossRef Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453–8.CrossRef
27.
go back to reference Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250–8.CrossRef Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250–8.CrossRef
28.
go back to reference Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e210–71.PubMed Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e210–71.PubMed
29.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRef
30.
go back to reference Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.CrossRef Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221–30.CrossRef
31.
go back to reference Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135(2):201–3.CrossRef Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135(2):201–3.CrossRef
32.
go back to reference El Moheb M, Nicolas J, Khamis AM, Iskandarani G, Akl EA, Refaat M. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. Cochrane Database Syst Rev. 2018;12(12):CD012738.PubMed El Moheb M, Nicolas J, Khamis AM, Iskandarani G, Akl EA, Refaat M. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. Cochrane Database Syst Rev. 2018;12(12):CD012738.PubMed
33.
go back to reference Solomon SD, Anavekar N, Skali H, McMurray J, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13;112(24):3738–44.CrossRef Solomon SD, Anavekar N, Skali H, McMurray J, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13;112(24):3738–44.CrossRef
34.
go back to reference Gatzoulis KA, Dilaveris P, Arsenos P, et al. Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design - A two-step, multifactorial, electrophysiology-inclusive approach. Hellenic J Cardiol. 2021:62(2):169–172. Gatzoulis KA, Dilaveris P, Arsenos P, et al. Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design - A two-step, multifactorial, electrophysiology-inclusive approach. Hellenic J Cardiol. 2021:62(2):169–172.
35.
go back to reference van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J AmCollCardiol. 2011;57(5):556–62.CrossRef van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J AmCollCardiol. 2011;57(5):556–62.CrossRef
36.
go back to reference Jablonowski R, Chaudhry U, van der Pals J, et al. Cardiovascular magnetic resonance to predict appropriate implantable cardioverter defibrillator therapy in ischemic and nonischemic cardiomyopathy patients using late gadolinium enhancement border zone: comparison of four analysis methods. Circ Cardiovasc Imaging. 2017 Sep;10(9):e006105.CrossRef Jablonowski R, Chaudhry U, van der Pals J, et al. Cardiovascular magnetic resonance to predict appropriate implantable cardioverter defibrillator therapy in ischemic and nonischemic cardiomyopathy patients using late gadolinium enhancement border zone: comparison of four analysis methods. Circ Cardiovasc Imaging. 2017 Sep;10(9):e006105.CrossRef
Metadata
Title
The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis
Authors
Ioannis Anagnostopoulos
Maria Kousta
Charalampos Kossyvakis
Eleni Lakka
Nikolaos Taxiarchis Paraskevaidis
Nikolaos Schizas
Nikolaos Alexopoulos
Spyridon Deftereos
Georgios Giannopoulos
Publication date
03-07-2021

Other articles of this Issue 3/2022

Journal of Interventional Cardiac Electrophysiology 3/2022 Go to the issue